» Articles » PMID: 14638963

Vagus Nerve Stimulation for Essential Tremor: a Pilot Efficacy and Safety Trial

Overview
Journal Neurology
Specialty Neurology
Date 2003 Nov 26
PMID 14638963
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To assess the safety and efficacy of vagus nerve stimulation (VNS) for essential tremor (ET).

Methods: This was a pilot open-treatment trial at three centers, with masked videotape tremor assessments. Inclusion required a severity score of 3 or 4 on the Tremor Rating Scale (TRS) in one or both hands. At baseline, tremor was assessed with TRS and Unified Tremor Rating Assessment (UTRA), accelerometry, and a videotape protocol. The VNS device was implanted with leads placed around the left cervical vagus nerve. Stimulation was adjusted over 4 weeks before the repeat tremor assessments. Two raters masked to the study visit scored the videotapes.

Results: Nine subjects participated, with a mean age of 65 years and a mean age at onset of tremor of 24. Investigators rated hand tremor as mildly improved (TRS 2.3 +/- 0.7 during VNS vs 3.0 +/- 0.4 during baseline, p = 0.06). Accelerometry-measured total power improved 50.2 +/- 31.8% (p < 0.01). Videotape tremor scores were highly correlated between the masked raters and revealed no changes in tremor scores with treatment. VNS was well tolerated, with the most common adverse events being stimulation related.

Conclusions: VNS was judged by investigators to mildly improve upper extremity tremor. This finding was not confirmed in videotape scoring by masked raters. VNS is not likely to have a clinically meaningful effect on ET.

Citing Articles

Recent Advances in Triboelectric Nanogenerators: From Technological Progress to Commercial Applications.

Choi D, Lee Y, Lin Z, Cho S, Kim M, Ao C ACS Nano. 2023; 17(12):11087-11219.

PMID: 37219021 PMC: 10312207. DOI: 10.1021/acsnano.2c12458.


A master protocol to investigate a novel therapy acetyl-L-leucine for three ultra-rare neurodegenerative diseases: Niemann-Pick type C, the GM2 gangliosidoses, and ataxia telangiectasia.

Fields T, Patterson M, Bremova-Ertl T, Belcher G, Billington I, Churchill G Trials. 2021; 22(1):84.

PMID: 33482890 PMC: 7821839. DOI: 10.1186/s13063-020-05009-3.


Vagal nerve stimulation for pharmacoresistant epilepsy in children.

Hauptman J, Mathern G Surg Neurol Int. 2012; 3(Suppl 4):S269-74.

PMID: 23230532 PMC: 3514916. DOI: 10.4103/2152-7806.103017.


Video Rating in Neurodegenerative Disease Clinical Trials: The Experience of PRION-1.

Carswell C, Ranopa M, Pal S, Macfarlane R, Siddique D, Thomas D Dement Geriatr Cogn Dis Extra. 2012; 2(1):286-97.

PMID: 22962552 PMC: 3435531. DOI: 10.1159/000339730.


Vagus nerve stimulation effective for focal motor seizures and focal interictal parkinsonian symptoms. A case report.

Bokkala-Pinninti S, Pinninti N, Jenssen S J Neurol. 2007; 255(2):301-2.

PMID: 17994309 DOI: 10.1007/s00415-007-0723-4.